Financial PerformanceA significant $8.7 million charge in the cost of goods sold is attributed to scrap costs, indicating inefficiencies in the manufacturing process.
Operational ChallengesStaffing constraints and infrastructural capacity issues are limiting the number of patients that can be treated monthly, impacting overall infusion volumes.
Product LaunchInitial metrics show a slow launch, with only about 10-15% of enrolled patients receiving the commercial Amtagvi infusion in the first quarter after approval.